Considering that CYP26A1 is a key enzyme responsible for RA degradation, patients who express lower levels of CYP26A1 should have higher levels of RA in their tumor cells, which should upregulate RA signaling activity and endow CRC patients with better survival. The gene discussed is CYP26A1; the disease is colorectal carcinoma.